- Home
- CSTL vs SWIM Comparison
CSTL vs SWIM Comparison
Compare CSTL & SWIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTL | SWIM |
|---|---|---|
| Founded | 2007 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Plastic Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.1M | 695.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CSTL | SWIM |
|---|---|---|
| Price | $21.16 | $5.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | ★ $45.50 | $6.75 |
| AVG Volume (30 Days) | 468.8K | ★ 731.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 160.00 |
| EPS | N/A | ★ N/A |
| Revenue | $344,229,000.00 | ★ $545,912,000.00 |
| Revenue This Year | $2.42 | $10.95 |
| Revenue Next Year | $12.69 | $6.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.66 | ★ 7.35 |
| 52 Week Low | $14.59 | $4.64 |
| 52 Week High | $44.28 | $8.97 |
Technical Indicators
Market Signals| Indicator | CSTL | SWIM |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 47.55 |
| Support Level | $17.72 | $5.04 |
| Resistance Level | $24.46 | $6.88 |
| Average True Range (ATR) | 1.12 | 0.24 |
| MACD | 0.37 | 0.06 |
| Stochastic Oscillator | 74.65 | 61.29 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. The company derives a majority of its revenue from the United States.